{"name":"Sinotau Pharmaceutical Group","slug":"sinotau-pharmaceutical-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"89Zr-CD147","genericName":"89Zr-CD147","slug":"89zr-cd147","indication":"Non-small cell lung cancer","status":"phase_1"},{"name":"Lutetium[177Lu] Oxodotreotide Injection","genericName":"Lutetium[177Lu] Oxodotreotide Injection","slug":"lutetium-177lu-oxodotreotide-injection","indication":"Neuroendocrine tumors (NET) expressing somatostatin receptors","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"XTR004","genericName":"XTR004","slug":"xtr004","indication":"Type 2 diabetes","status":"phase_3"},{"name":"XTR006","genericName":"XTR006","slug":"xtr006","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"89Zr-CD147","genericName":"89Zr-CD147","slug":"89zr-cd147","phase":"phase_1","mechanism":"Targeting CD147","indications":["Non-small cell lung cancer","Breast cancer"],"catalyst":""},{"name":"Lutetium[177Lu] Oxodotreotide Injection","genericName":"Lutetium[177Lu] Oxodotreotide Injection","slug":"lutetium-177lu-oxodotreotide-injection","phase":"phase_3","mechanism":"Lutetium-177 oxodotreotide is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells and delivers targeted radiation therapy.","indications":["Neuroendocrine tumors (NET) expressing somatostatin receptors","Gastroenteropancreatic neuroendocrine tumors (GEP-NET)"],"catalyst":""},{"name":"XTR004","genericName":"XTR004","slug":"xtr004","phase":"phase_3","mechanism":"XTR004 is a small molecule targeting the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"XTR006","genericName":"XTR006","slug":"xtr006","phase":"phase_3","mechanism":"XTR006 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPcm85aWxDbkItTmdadFl0ZDdNc05zdEdwUUVhTlE3NS1UY0hnV19DdEtkNlJzcTlMMFNxb1BMRm9HVDNOZW9aNkdha2QyTWxtUExndEoxY05NWERIZzFsYnB2RmFiZlpaYjR1RklmYklZTVFfalJuN1p0X2E0VUhERXRKa1pTbW1uaVE?oc=5","date":"2025-11-27","type":"pipeline","source":"ThinkChina","summary":"Where China stands in the nuclear medicine gold rush - ThinkChina","headline":"Where China stands in the nuclear medicine gold rush","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxONElWOU54aEJrOWJKTWFabVcwWnByMnVnc1lGakg3TjVyc2YyYlFBSE1oM3FLelVlLTFXZk1TSkZpZndBSTB4ZkgwUVpxXzJDVXlWUTVDREdpclkzMFBwdl9WY3ZJeTRiRGdQU19nOEZDNkR2YlhDMjBVZmJnaXlPS3I3MWxHWE5EN1hKcjJ4ZHF6SXVG?oc=5","date":"2025-06-05","type":"pipeline","source":"thebambooworks.com","summary":"Sinotau aims to become Hong Kong’s ‘first nuclear-medicine stock’ - thebambooworks.com","headline":"Sinotau aims to become Hong Kong’s ‘first nuclear-medicine stock’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNYkt6eFd2MzhaeVl3ODhOUDlrcG1jdmxhU01tWFFHOUdhRm92WGdySm15czZzYmJhdW1ITkpfSld5RHEwWnpPa1Q4Q0tPRnZmblBYSUc1V1hPS2FFSEVBcWRkT3lQM1ZaWk5JaDBGZzdQMlpKakM4OWhDV3pmdDh2LVJCYzNJeEdfZ2pqczhkMWpwMWR2Z19tSXhtZVpZdWQtQjNyZjR1WU0?oc=5","date":"2025-05-26","type":"regulatory","source":"富途牛牛","summary":"Xiantong Pharmaceuticals-B, the first company in China to receive approval for the sale of innovative radioactive drugs, has submitted an IPO prospectus and plans to list in Hong Kong. - 富途牛牛","headline":"Xiantong Pharmaceuticals-B, the first company in China to receive approval for the sale of innovative radioactive drugs,","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE1WN3hBRmg1WUp2bWRhZHhXQ2Zyc19KRXAxLWxtak96Q1BkaVJtenh3clI2WkwyaURVQXBLQXFBYURLcHBIUVNVaTFTTm5OMl9sLXVSb1RtY3JzbS0wc3RZWENzUEVrdDlONEhZVHBUWmRMTGlSWnBFWFRQSEM?oc=5","date":"2024-05-01","type":"pipeline","source":"jnm.snmjournals.org","summary":"Landscape of Nuclear Medicine in China and Its Progress on Theranostics - jnm.snmjournals.org","headline":"Landscape of Nuclear Medicine in China and Its Progress on Theranostics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxQcm1rQkJKS1JwZUtqYjllY1NOSk5WRDBxOUN4UDJ2YjJiYXBMTnlQcnAyWENsMm91dDFPNVhtalpjZWlPNkMtaFp4QWVqZ21CY2Q0alJScFpOSnRlbk9mdUNpU3dqZWlzWGRmTlBPU1Y1VEgycnkxdjlOTWloTkh6RjVyWi1Fd01NbXhTTVBxTWg4aWJ3bzd5ajkyTzlTSmhxLXZyUURNSnNUbF9GVjNWbXFlT0hEOTVEZHJyT2l0bUs0ZWxCclp0VUZrOTk4V3V5Z1EzYWhEbU14aHdoYjlka1otN1BxTzNaeFRiTGg1a0FYcmxCRGJMWTUzbHhGSTllRzZLT294cW02aWVrSFo4Sk9FZkZHWVlINkdndWZwMnV0OXcwWGxnUEtPWVA?oc=5","date":"2023-11-30","type":"pipeline","source":"IANS","summary":"IANS - IANS","headline":"IANS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxNWEY0ZVdrM19VWmFjZGk3NDh0NjdYTFF1c1JGOGdyRzYxYWx5REVpbHJ6NW9IZmdfODFEYXFrLUlvMzdOTkNSWWZkb2VKNDQwMDkwN2x1bEhuNDVqRXVVR2lmR1lLUm40TkdJUXdPZXBqeGw2Vnp0R2M0Zml2QTNCbFpkV2haU3NiNzh5MXU0NElzSnVBc2E0ZmV2WEoxRjZhN0FTRWJYb1o4dERIbjNSUzFERHdQWTNYNXFzUjl4N25YVE9yaHRXdVIxTGdQYW8wNW1EQm9hbHJBck1HbHQ3SERpQmhwM0FTQ1FNWnNDQU9tVy1RMzR0d1kxcWRzakZ0LVRYN1lQRmZEUWxF?oc=5","date":"2023-10-24","type":"regulatory","source":"BioSpace","summary":"Life Molecular Imaging and Sinotau Pharmaceutical Group Announce the Regulatory Approval of their Amyloid PET Imaging Radiopharmaceutical Neuraceq® in China - BioSpace","headline":"Life Molecular Imaging and Sinotau Pharmaceutical Group Announce the Regulatory Approval of their Amyloid PET Imaging Ra","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNZ3BVbldXcDFnUlVxMjNUUnA4NDVHZXg5OWQ3cmY5SEgybi0xTDhhZE55Y1VVTEo5eEoxVmZEU05HYlRBLVVlWk5sYjhLeU1oVDBpcjBna08wQVJzX28yRlVKa3hLZ2FaVzZmNktUUEtzSENYdVNFMm1FajllcWk1NWI4Sm41TGJ3bjh2aWlEOTViaGJpZ001QktqQTBJNnctVUo4WUFYYlpkb2paem5RMkY3UGlBcHRwN2QyUkN0eVJrcjll?oc=5","date":"2023-10-18","type":"deal","source":"Urology Times","summary":"Collaboration aims to make flotufolastat F 18 available in China for prostate cancer imaging - Urology Times","headline":"Collaboration aims to make flotufolastat F 18 available in China for prostate cancer imaging","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOcFN4WDBHZk4xM2pBMXBiREFzQlk1MUF0ZFhycTd0SWdJLXcybFZhbDdlT0JtVGpPUDhHOFVOQUQwTDlxOG90SnlFUEp5S1Q3RmhMek13NWY5a2I5blptTzdlbE9TaThyYktETHVueTB0RW1jLW9RR2VJSDBOaEZCcHloTGdUVURzbGM1TG40R3hiWkFmVEpELTE3c3hqdVE?oc=5","date":"2023-10-17","type":"trial","source":"Oncology Pipeline","summary":"First phase 1 starters challenge Pluvicto and Revolution | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"First phase 1 starters challenge Pluvicto and Revolution | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNYzZrUGppOTl2RnAxdm1GMTJnZzNURk1OeGEwZXc5MTZYQll5RWJiZWFiX2FPWFRka1RNYldOanB5aHZ2alhYZlZwQkdMd0liaWNzMEhia3Vtd21KZ1pDV3pvTkhERmY4b2Z0WElMZzJKSXVuemdXY0dXQzFqcWRSQ09VbHZEeHd3VXBqTmpza0x1a1JPVlFxcEVudXBSaUFiQUp6RW1VVlFiXzJ3d2pDMmN3?oc=5","date":"2023-07-03","type":"pipeline","source":"BioWorld News","summary":"Sinotau nets $152M in financing to develop radiopharmaceuticals in China - BioWorld News","headline":"Sinotau nets $152M in financing to develop radiopharmaceuticals in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5qNEFXVlNMZGVFTk4wOEpmd29lYUkza0Q3RzRxT08tQ2xKVWhpd2lYRGhWX09seERWOG52R2xIZTV6MFQ3ZXNXOWU5UDBfUDJ4Wk9OOGNTVFFuakhsWGxqRGpiaF93MkhWZVN2eHZn?oc=5","date":"2020-03-19","type":"pipeline","source":"Straits Research","summary":"Radiopharmaceutical Market Size, Growth & Trends By 2033 - Straits Research","headline":"Radiopharmaceutical Market Size, Growth & Trends By 2033","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":1,"phase_3":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}